346 related articles for article (PubMed ID: 14500386)
1. Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose.
Aft RL; Lewis JS; Zhang F; Kim J; Welch MJ
Cancer Res; 2003 Sep; 63(17):5496-504. PubMed ID: 14500386
[TBL] [Abstract][Full Text] [Related]
2. Internal radiotherapy with copper-64-diacetyl-bis (N4-methylthiosemicarbazone) reduces CD133+ highly tumorigenic cells and metastatic ability of mouse colon carcinoma.
Yoshii Y; Furukawa T; Kiyono Y; Watanabe R; Mori T; Yoshii H; Asai T; Okazawa H; Welch MJ; Fujibayashi Y
Nucl Med Biol; 2011 Feb; 38(2):151-7. PubMed ID: 21315269
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.
Valtorta S; Belloli S; Sanvito F; Masiello V; Di Grigoli G; Monterisi C; Fazio F; Picchio M; Moresco RM
J Nucl Med; 2013 Jul; 54(7):1106-12. PubMed ID: 23699667
[TBL] [Abstract][Full Text] [Related]
4. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).
Yuan H; Schroeder T; Bowsher JE; Hedlund LW; Wong T; Dewhirst MW
J Nucl Med; 2006 Jun; 47(6):989-98. PubMed ID: 16741309
[TBL] [Abstract][Full Text] [Related]
5. Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models.
Tanaka T; Furukawa T; Fujieda S; Kasamatsu S; Yonekura Y; Fujibayashi Y
Nucl Med Biol; 2006 Aug; 33(6):743-50. PubMed ID: 16934693
[TBL] [Abstract][Full Text] [Related]
6. (64)Cu-ATSM therapy targets regions with activated DNA repair and enrichment of CD133(+) cells in an HT-29 tumor model: Sensitization with a nucleic acid antimetabolite.
Yoshii Y; Furukawa T; Matsumoto H; Yoshimoto M; Kiyono Y; Zhang MR; Fujibayashi Y; Saga T
Cancer Lett; 2016 Jun; 376(1):74-82. PubMed ID: 26996296
[TBL] [Abstract][Full Text] [Related]
7. Copper-64-diacetyl-bis (N4-methylthiosemicarbazone) accumulates in rich regions of CD133+ highly tumorigenic cells in mouse colon carcinoma.
Yoshii Y; Furukawa T; Kiyono Y; Watanabe R; Waki A; Mori T; Yoshii H; Oh M; Asai T; Okazawa H; Welch MJ; Fujibayashi Y
Nucl Med Biol; 2010 May; 37(4):395-404. PubMed ID: 20447549
[TBL] [Abstract][Full Text] [Related]
8. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.
Dence CS; Ponde DE; Welch MJ; Lewis JS
Nucl Med Biol; 2008 Aug; 35(6):713-20. PubMed ID: 18678357
[TBL] [Abstract][Full Text] [Related]
9. Basic characterization of 64Cu-ATSM as a radiotherapy agent.
Obata A; Kasamatsu S; Lewis JS; Furukawa T; Takamatsu S; Toyohara J; Asai T; Welch MJ; Adams SG; Saji H; Yonekura Y; Fujibayashi Y
Nucl Med Biol; 2005 Jan; 32(1):21-8. PubMed ID: 15691658
[TBL] [Abstract][Full Text] [Related]
10. Retention of the radiotracers 64Cu-ATSM and 64Cu-PTSM in human and murine tumors is influenced by MDR1 protein expression.
Liu J; Hajibeigi A; Ren G; Lin M; Siyambalapitiyage W; Liu Z; Simpson E; Parkey RW; Sun X; Oz OK
J Nucl Med; 2009 Aug; 50(8):1332-9. PubMed ID: 19617332
[TBL] [Abstract][Full Text] [Related]
11. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.
O'Donoghue JA; Zanzonico P; Pugachev A; Wen B; Smith-Jones P; Cai S; Burnazi E; Finn RD; Burgman P; Ruan S; Lewis JS; Welch MJ; Ling CC; Humm JL
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1493-502. PubMed ID: 15817355
[TBL] [Abstract][Full Text] [Related]
12. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).
Dehdashti F; Grigsby PW; Lewis JS; Laforest R; Siegel BA; Welch MJ
J Nucl Med; 2008 Feb; 49(2):201-5. PubMed ID: 18199612
[TBL] [Abstract][Full Text] [Related]
13. Monitoring the effect of mild hyperthermia on tumour hypoxia by Cu-ATSM PET scanning.
Myerson RJ; Singh AK; Bigott HM; Cha B; Engelbach JA; Kim J; Lamoreaux WT; Moros E; Novak P; Sharp TL; Straube W; Welch MJ; Xu M
Int J Hyperthermia; 2006 Mar; 22(2):93-115. PubMed ID: 16754595
[TBL] [Abstract][Full Text] [Related]
14. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation.
Lewis JS; Sharp TL; Laforest R; Fujibayashi Y; Welch MJ
J Nucl Med; 2001 Apr; 42(4):655-61. PubMed ID: 11337556
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model.
Lewis JS; McCarthy DW; McCarthy TJ; Fujibayashi Y; Welch MJ
J Nucl Med; 1999 Jan; 40(1):177-83. PubMed ID: 9935074
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer.
Takahashi N; Fujibayashi Y; Yonekura Y; Welch MJ; Waki A; Tsuchida T; Sadato N; Sugimoto K; Itoh H
Ann Nucl Med; 2000 Oct; 14(5):323-8. PubMed ID: 11108159
[TBL] [Abstract][Full Text] [Related]
17. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM.
Burgman P; O'Donoghue JA; Lewis JS; Welch MJ; Humm JL; Ling CC
Nucl Med Biol; 2005 Aug; 32(6):623-30. PubMed ID: 16026709
[TBL] [Abstract][Full Text] [Related]
18. Intra-tumoral distribution of (64)Cu-ATSM: a comparison study with FDG.
Obata A; Yoshimoto M; Kasamatsu S; Naiki H; Takamatsu S; Kashikura K; Furukawa T; Lewis JS; Welch MJ; Saji H; Yonekura Y; Fujibayashi Y
Nucl Med Biol; 2003 Jul; 30(5):529-34. PubMed ID: 12831991
[TBL] [Abstract][Full Text] [Related]
19. Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): An agent for radiotherapy.
Lewis J; Laforest R; Buettner T; Song S; Fujibayashi Y; Connett J; Welch M
Proc Natl Acad Sci U S A; 2001 Jan; 98(3):1206-11. PubMed ID: 11158618
[TBL] [Abstract][Full Text] [Related]
20. Dose painting based on tumor uptake of Cu-ATSM and FDG: a comparative study.
Clausen MM; Hansen AE; Lundemann M; Hollensen C; Pommer T; Munck Af Rosenschöld P; Kristensen AT; Kjær A; McEvoy FJ; Engelholm SA
Radiat Oncol; 2014 Oct; 9():228. PubMed ID: 25319766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
